Takeda announces positive Phase 2 results for mezagitamab in ITP, plans Phase 3 trial in 2024.
Takeda announced positive Phase 2 topline results for mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP). The TAK-079-1004 trial showed that mezagitamab, a fully human immunoglobulin IgG1 monoclonal antibody, was generally safe and well tolerated. Based on these results, Takeda plans to initiate a global Phase 3 trial in ITP in fiscal year 2024.
March 13, 2024
5 Articles